S01-Pharm-E01: AbbVie 3Q 2024
Quarterly Briefing · W Section Production
Audio is streamed directly from the publisher (content.rss.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode of The Quarterly Briefing, we dive deep into AbbVie's financial performance for Q3 2024, analyzing key strategies in immunology, oncology, and neuroscience. We explore the impact of Humira's decline, the promising future of Skyrisi and Rynvok, advancements in oncology with Imbruvica and Venclexta, and innovations in neuroscience with Graylar and new Parkinson's treatments. Discover how AbbVie's strategic acquisitions and use of digital technologies like AI are shaping their future, ensuring robust growth despite economic uncertainties. Join us for an informative and engaging look into one of the leading pharmaceutical companies.
00:00 Introduction to The Quarterly Briefing
01:19 Deep Dive into AbbVie's Q3 2024 Performance
01:40 AbbVie's Immunology Strategy
04:18 Exploring AbbVie's Oncology Portfolio
05:13 AbbVie's Neuroscience Innovations
06:49 Financial Health and Strategic Acquisitions
11:55 Commitment to Innovation and Social Responsibility
15:30 Conclusion and Future Outlook
17:39 Closing Remarks and Listener Engagement